The historical development of interferons as multiple sclerosis therapies

Journal of Molecular Medicine

Volumn 75, Issue 2, 1997, Pages 89-94

  Johnson, Kenneth P ^a  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

chronic progressive; interferon; multiple sclerosis; relapsing remitting

Indexed keywords

BETA INTERFERON;

CASE REPORT; CEREBROSPINAL FLUID; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESEARCH; HUMAN; MULTIPLE SCLEROSIS; PATIENT SELECTION; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; FEMALE; HISTORY, 20TH CENTURY; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; PREGNANCY; RANDOMIZED CONTROLLED TRIALS; RECURRENCE;

EID: 0030997082     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090050093     Document Type: Review

References (31)

1. Isaacs A, Lindemann J (1957) Virus interference. I. The interferon. Proc R Soc London (Biol) 147:258-267
2. Johnson HM, Bazer FW, Szente BE, Jarpe MA (1994) How interferons fight disease. Sci Am 24:68-75
3. Neighbour PA, Miller AE, Bloom BR (1981) Interferon responses of leukocytes in multiple sclerosis. Neurology 31: 561-566
4. Fog T (1980) Interferon treatment of multiple sclerosis patients: a pilot study. In: Boese A (ed) Search for the cause of multiple sclerosis and other chronic diseases of the nervous system. Verlag Chemie, Weinheim, pp 491-493
5. Ververken D, Carton H, Billiau A (1979) Intrathecal administration of interferon in MS patients. In: Karcher D, Lowenthal A, Strosberg AD (eds) Humoral immunity in neurological disease. Plenum, New York, pp 625-627
6. Jacobs L, Johnson, KP (1994) A brief history of the use of interferons as treatment of multiple sclerosis. Arch Neurol 51: 1245-1252
7. 8 units per ml. J Gen Virol 39:541-543
8. Knobler RL, Panitch HS, Braheny SL et al (1984) Systemic alpha interferon therapy in multiple sclerosis. Neurology 34: 1273-1279
9. Panitch HS, Francis GS, Hooper CJ et al (1985) Serial immunological studies in multiple sclerosis patients treated systemically with human alpha interferon. Ann Neurol 18:434-438
10. Jacobs L, O'Malley J, Freeman A, Ekes R (1981) Intrathecal interferon reduces exacerbation of multiple sclerosis. Science 214:1026-1028
11. Jacobs L, O'Malley JA, Freeman A, Ekes R, Reese PA (1985) Intrathecal interferon in the treatment of multiple sclerosis: patient follow-up. Arch Neurol 42:841-847
12. Jacobs L, Salazar AM, Herndon R et al (1986) Multicenter double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis. Lancet 11:1411-1413
13. Kastrukoff LF, Oger JJ, Tourtellotte WW et al (1990) Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. I. clinical and MRI evaluation. Neurology 40:479-486
14. AUSTIMS Research Group (1989) Interferon and transfer factor in the treatment of multiple sclerosis: a double-blind, placebo-controlled trial. J Neurol Neurosurg Psychiatry 52:566-574
15. Camenga DL, Johnson KP, Alter M et al (1986) Systemic recombinant α-2 interferon therapy in relapsing multiple sclerosis. Arch Neurol 43:1239-1246
16. Hirsch RL, Johnson KP, Camenga DL (1988) The placebo effect during a double-blind trial of recombinant alpha-2 interferon in multiple sclerosis patients: immunological and clinical findings. Int J Neurosci 39:189-196
17. Panitch HS, Hirsch RL, Haley AS, Johnson KP (1987) Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet I, 893-895
18. Panitch HS, Hirsch RL, Schindler J, Johnson KP (1987) Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 37:1097-1102
19. Panitch HS (1994) Influence of infection on exacerbations of multiple sclerosis. Ann Neurol 36:S25-S28
20. Johnson KP, Knobler RL, Greenstein JI, Panitch HS et al (1990) Recombinant human interferon beta treatment of relapsing-remitting multiple sclerosis: pilot study results. Neurology 40: 261 (abstract)
21. Knobler RL, Greenstein JI, Johnson KP et al (1993) Systemic recombinant human interferon-β treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. J Inf Res 13:333-340
22. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 33:1444-1452
23. The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661
24. Paty DW, Li DKB, the UBC MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:662-667
25. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45:1277-1285
26. Stone LA, Frank JA, Albert PSH et al (1995) The effect of interferon B on blood brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 37:611-619
27. Jacobs LD, Cookfair DL, Rudick RA et al (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285-294
28. Brod SA, Marshall GD, Henninger E et al (1996) Oral interferon-a: Biologic effects in normal individuals and subjects with relapsing remitting multiple sclerosis. Neurology 46: A107 (abstract)
29. Durelli L, Bongioanni MR, Ferrero B et al (1996) Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: Disease activity resumes after stopping treatment. Neurology (in press)
30. Johnson KP, Brooks BR, Cohen JA et al (1995) Copolymer I reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 45:1268-1276
31. Milo R, Panitch HS (1995) Additive effects of copolymer-1 and interferon beta-1b on the immune responses to myelin basic protein. J Neuroimmunol 61:185-193